Compare AVLN & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | IART |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 1996 |
| Metric | AVLN | IART |
|---|---|---|
| Price | $27.52 | $16.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 12 |
| Target Price | ★ $62.25 | $19.56 |
| AVG Volume (30 Days) | 192.8K | ★ 725.5K |
| Earning Date | 08-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.40 |
| Revenue Next Year | N/A | $3.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $8.70 |
| 52 Week High | $40.17 | $20.49 |
| Indicator | AVLN | IART |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 50.17 |
| Support Level | $25.86 | $16.04 |
| Resistance Level | $30.45 | $16.38 |
| Average True Range (ATR) | 2.25 | 0.62 |
| MACD | -0.56 | 0.14 |
| Stochastic Oscillator | 14.12 | 74.87 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.